Atopic Dermatitis: key endpoint results by drug
The key endpoints of Atopic Dermatitis trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Atopic Dermatitis page.
EASI-75
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| abrocitinib | 39.7% | 11.8% | +27.9 | 100 mg · wk 12 · n 156 | NCT03349060 Phase 3, primary |
| astegolimab | 27.3% | 18.8% | +8.5 | wk 16 · n 33 | NCT03747575 Phase 2, secondary |
| baricitinib | 31.5% | 17.2% | +14.3 | 4 mg · wk 16 · n 92 | NCT03428100 Phase 3, primary |
| brepocitinib | 32.4% | 35.1% | −2.7 | 0.1% Cream QD · wk 6 · n 37 | NCT03903822 Phase 2, secondary |
| crisaborole | 46.4% | 27.6% | +18.8 | 2% twice a day · wk 4.14 · n 260 | NCT04360187 Phase 3, secondary |
| dupilumab | 62.6% | 29.6% | +33 | 300 mg Q2W · wk 16 · n 107 | NCT02755649 Phase 3, primary |
| etrasimod | 38.3% | 26.1% | +12.2 | 2 mg · wk 12 · n 47 | NCT04162769 Phase 2, secondary |
| lebrikizumab | 51.2% | 13.4% | +37.8 | 250 mg Q2W · wk 16 · n 123 | NCT04760314 Phase 3, primary |
| nemolizumab | 43.5% | 29% | +14.5 | 30 mg · wk 16 · n 620 | NCT03985943 Phase 3, primary |
| Nitrosomonas eutropha (B244) | 27.7% | 15.8% | +11.9 | O.D. 5.0 · wk 4 · n 166 | NCT04490109 Phase 2, secondary |
| Rademikibart | 58.6% | 22.6% | +36 | 300mg Q2W · wk 16 · n 219 | NCT05017480 Phase 2, secondary |
| rilzabrutinib | 29.6% | 29% | +0.6 | wk 16 · n 27 | NCT05018806 Phase 2, secondary |
| risankizumab | 21.7% | 11.8% | +9.9 | 300 mg · wk 16 · n 69 | NCT03706040 Phase 2, primary |
| Roflumilast (Zoryve) | 43.2% | 22% | +21.2 | 0.15% cream · wk 4 · n 433 | NCT04773587 Phase 3, secondary |
| spesolimab | 0.2% | 0.1% | +0.1 | 600 mg intravenous every 4 weeks · wk 16 · n 33 | NCT03822832 Phase 2, secondary |
| Tapinarof | 55.8% | 22.9% | +32.9 | wk 8 · n 270 | NCT05014568 Phase 3, secondary |
| tezepelumab | 24.4% | 19.8% | +4.6 | 280 mg · wk 12 · n 55 | NCT02525094 Phase 2, secondary |
| tozorakimab | 10.5% | 7.1% | +3.4 | Dose 1 · wk 16 · n 19 | NCT04212169 Phase 2, secondary |
| tralokinumab | 25% | 12.7% | +12.3 | 300 mg Q2W · wk 16 · n 601 | NCT03131648 Phase 3, primary |
| upadacitinib | 60.1% | 13.3% | +46.8 | 15 mg QD · wk 16 · n 276 | NCT03607422 Phase 3, primary |
Drugs checked with no result here: 36 not reported, 13 trial running, 6 not posted.
IGA 0/1 with 2-point improvement
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| abrocitinib | 27.8% | 6.3% | +21.5 | 100mg QD · wk 12 · n 56 | NCT02780167 Phase 2, primary |
| baricitinib | 21.7% | 9.7% | +12 | 4 mg · wk 16 · n 92 | NCT03428100 Phase 3, secondary |
| lebrikizumab | 33.4% | 6.1% | +27.3 | 250 mg Q2W · wk 16 · n 123 | NCT04760314 Phase 3, primary |
| nemolizumab | 33.3% | 12.3% | +21 | 30 mg · wk 16 · n 57 | NCT03100344 Phase 2, secondary |
| spesolimab | 9.1% | 0% | +9.1 | 600 mg intravenous every 4 weeks · wk 16 · n 33 | NCT03822832 Phase 2, secondary |
| tezepelumab | 19.3% | 12.8% | +6.5 | 280 mg · wk 12 · n 55 | NCT02525094 Phase 2, secondary |
| tralokinumab | 11.6% | 11.8% | −0.2 | wk 12 · n 50 | NCT02347176 Phase 2, primary |
Drugs checked with no result here: 43 not reported, 17 trial running, 8 not posted.
EASI-90
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| abrocitinib | 28.5% | 14.6% (Dupilumab) | — | 200 mg QD · wk 4 · n 354 | NCT04345367 Phase 3, primary |
| baricitinib | 16% | 4.8% | +11.2 | 4 mg · wk 16 · n 125 | NCT03334396 Phase 3, secondary |
| dupilumab | 35.7% | 7.6% | +28.1 | 300 mg q2w · wk 16 · n 224 | NCT02277743 Phase 3, secondary |
| etrasimod | 14.9% | 10.9% | +4 | 2 mg · wk 12 · n 47 | NCT04162769 Phase 2, secondary |
| lebrikizumab | 34.3% | 9.8% | +24.5 | 250 mg Q2W · wk 16 · n 123 | NCT04760314 Phase 3, secondary |
| nemolizumab | 33.3% | 8.8% | +24.5 | 30 mg · wk 16 · n 57 | NCT03100344 Phase 2, secondary |
| Nitrosomonas eutropha (B244) | 15.1% | 5.8% | +9.3 | O.D. 5.0 · wk 4 · n 166 | NCT04490109 Phase 2, secondary |
| Rademikibart | 33.4% | 6.4% | +27 | 300mg Q2W · wk 16 · n 219 | NCT05017480 Phase 2, secondary |
| risankizumab | 8.7% | 2.9% | +5.8 | 300 mg · wk 16 · n 69 | NCT03706040 Phase 2, secondary |
| Roflumilast (Zoryve) | 17.4% | 17.8% | −0.4 | 0.05% · wk 4 · n 46 | NCT03916081 Phase 2, secondary |
| Tapinarof | 29.8% | 6.1% | +23.7 | wk 8 · n 270 | NCT05014568 Phase 3, secondary |
| tozorakimab | 0% | 0% | ±0 | Dose 1 · wk 16 · n 19 | NCT04212169 Phase 2, secondary |
| tralokinumab | 14.5% | 4.1% | +10.4 | 300 mg Q2W · wk 16 · n 601 | NCT03131648 Phase 3, secondary |
| upadacitinib | 42.4% | 5.4% | +37 | 15 mg QD · wk 16 · n 276 | NCT03607422 Phase 3, secondary |
Drugs checked with no result here: 41 not reported, 14 trial running, 6 not posted.
EASI, % change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| abrocitinib | -60% | -28.6% | −31.4 | 100 mg · wk 12 · n 158 | NCT03575871 Phase 3, secondary |
| apremilast | -31.6% | -11.0% | −20.6 | 40 mg · wk 12 · n 63 | NCT02087943 Phase 2, primary |
| astegolimab | -51.5% | -58.2% | +6.8 | wk 16 · n 33 | NCT03747575 Phase 2, primary |
| baricitinib | -59.4% | -34.8% | −24.5 | 4 mg · wk 16 · n 70 | NCT03334396 Phase 3, secondary |
| brepocitinib | -58.3% | -44.4% | −13.9 | 0.1% Cream QD · wk 6 · n 37 | NCT03903822 Phase 2, primary |
| crisaborole | -59.9% | -42.8% | −17.1 | 2% twice a day · wk 4 · n 260 | NCT04360187 Phase 3, primary |
| dupilumab | 0.1% | 21.7% | −21.6 | 300 mg Q2W/QW · wk 36 · n 169 | NCT02395133 Phase 3, primary |
| etrasimod | -57.2% | -48.4% | −8.8 | 2 mg · wk 12 · n 47 | NCT04162769 Phase 2, primary |
| lebrikizumab | -64.2% | -25.3% | −39 | 250 mg Q2W · wk 16 · n 123 | NCT04760314 Phase 3, secondary |
| nemolizumab | -73.4% | -58.4% | −15 | 30 mg · wk 24 · n 57 | NCT03100344 Phase 2, primary |
| Rademikibart | -57.6% | -39.7% | −17.9 | 150 Q2W · wk 16 · n 57 | NCT04444752 Phase 2, primary |
| rilzabrutinib | -53.6% | -43.3% | −10.2 | wk 16 · n 24 | NCT05018806 Phase 2, primary |
| risankizumab | -45.4% | -28.5% | −16.8 | 300 mg · wk 16 · n 43 | NCT03706040 Phase 2, secondary |
| Roflumilast (Zoryve) | -69.4% | -55.8% | −13.5 | 0.05% · wk 4 · n 46 | NCT03916081 Phase 2, secondary |
| secukinumab | -5.0% | 5.3% | −10.2 | wk 16 · n 14 | NCT02594098 Phase 2, secondary |
| spesolimab | -37.9% | -12.3% | −25.6 | 600 mg intravenous every 4 weeks · wk 16 · n 28 | NCT03822832 Phase 2, primary |
| tezepelumab | -25.3% | -11.3% | −14 | 700 mg IV · wk 16.14 · n 9 | NCT00757042 Phase 1, secondary |
| tralokinumab | -77.8% | -73.5% | −4.3 | wk 16 · n 53 | NCT04587453 Phase 3, secondary |
| upadacitinib | -74.1% | -34.5% | −39.6 | 15 mg QD · wk 16 · n 246 | NCT03607422 Phase 3, secondary |
| ustekinumab | -39.4% | -37.5% | −1.9 | 90 mg · wk 12 · n 28 | NCT01945086 Phase 2, primary |
Drugs checked with no result here: 35 not reported, 14 trial running, 6 not posted.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 75 approved or late-stage drugs with a featured trial in Atopic Dermatitis were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.